Myelodysplastic syndromes: lost between two states?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

16 citing papers in PubMed.

1. Allelic expression patterns of imprinted and non-imprinted genes in cancer cell lines from multiple histologies.Clinical epigenetics · 2025
   Article
2. Increased copy number of imprinted genes in the chromosomal region 20q11-q13.32 is associated with resistance to antitumor agents in cancer cell lines.Clinical epigenetics · 2022
   Article
3. Realgar (α-AsChinese journal of integrative medicine · 2022
   Review
4. Hematopoietic stem and progenitor cell-restricted Cdx2 expression induces transformation to myelodysplasia and acute leukemia.Nature communications · 2020
   Article
5. Complex karyotype with novel translocation in pure erythroid leukemia patient.Hematology reports · 2015
   Article
6. Dynamics of ASXL1 mutation and other associated genetic alterations during disease progression in patients with primary myelodysplastic syndrome.Blood cancer journal · 2014
   Article
7. Acquired myelodysplasia or myelodysplastic syndrome: clearing the fog.Advances in hematology · 2013
   Review
8. Infections in myelodysplastic syndromes.Haematologica · 2012
   Review
9. Myeloid malignancies: mutations, models and management.BMC cancer · 2012
   Review
10. Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice.Proceedings of the National Academy of Sciences of the United States of America · 2011
    Article
11. Mutations and deletions of the SUZ12 polycomb gene in myeloproliferative neoplasms.Blood cancer journal · 2011
    Article
12. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes.Leukemia · 2011
    Article
13. NAD(P)H: quinone oxidoreductase 1 deficiency conjoint with marginal vitamin C deficiency causes cigarette smoke induced myelodysplastic syndromes.PloS one · 2011
    Article
14. Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias.BMC cancer · 2010
    Article
15. Molecular aspects of myeloproliferative neoplasms.International journal of hematology · 2010
    Review
16. Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias.Leukemia · 2010
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as